Adage Capital Partners’s Cogent Biosciences COGT Stock Holding History

Adage Capital Partners’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.94M	Hold	50,000	–	–	﹤0.01%	873
2026 Q1	$1.92M	Sell	50,000 -50,000	-50%	-$1.85M	﹤0.01%	839
2025 Q4	$3.55M	Sell	100,000 -462,000	-82%	-$13M	0.01%	794
2025 Q3	$8.07M	Buy	+562,000	New	+$6.66M	0.01%	670
2025 Q1	–	Sell	-4,300,000	Closed	-$33.5M	–	863
2024 Q4	$33.5M	Buy	4,300,000 +233,966	+6%	+$2.33M	0.06%	304
2024 Q3	$43.9M	Sell	4,066,034 -182,854	-4%	-$1.78M	0.08%	254
2024 Q2	$35.8M	Buy	4,248,888 +2,915,555	+219%	+$22.1M	0.07%	290
2024 Q1	$8.96M	Buy	+1,333,333	New	+$8.24M	0.02%	619
2023 Q4	–	Sell	-1,036,069	Closed	-$10.1M	–	872
2023 Q3	$10.1M	Sell	1,036,069 -100,000	-9%	-$1.19M	0.02%	559
2023 Q2	$13.5M	Sell	1,136,069 -250,544	-18%	-$2.87M	0.03%	508
2023 Q1	$15M	Buy	1,386,613 +350,000	+34%	+$4.48M	0.03%	510
2022 Q4	$12M	Sell	1,036,613 -110,037	-10%	-$1.36M	0.03%	592
2022 Q3	$17.1M	Sell	1,146,650 -80,000	-7%	-$1.1M	0.04%	470
2022 Q2	$11.1M	Buy	+1,226,650	New	+$8.37M	0.03%	645

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Adage Capital Partners's COGT Position: Q2 2026 in Review

Adage Capital Partners held its Cogent Biosciences (COGT) position steady in Q2 2026 at 50,000 shares worth $1.94M. The position accounts for ﹤0.01% of the portfolio, ranked #873.

Adage Capital Partners first reported a position in COGT in Q2 2022 and has held it in 14 quarters since. The position peaked at $43.9M in Q3 2024. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

Adage Capital Partners held 50,000 shares of Cogent Biosciences worth $1.94M as of Q2 2026.
Adage Capital Partners left its Cogent Biosciences share count unchanged in Q2 2026.
Cogent Biosciences made up ﹤0.01% of Adage Capital Partners's portfolio in Q2 2026, its #873 holding.
Adage Capital Partners first reported a position in Cogent Biosciences in Q2 2022 and has held it in 14 quarters since.
Adage Capital Partners's Cogent Biosciences position peaked at $43.9M in Q3 2024.
323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.